GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Wuhan Easy Diagnosis Biomedicine Co Ltd (SZSE:002932) » Definitions » Cyclically Adjusted FCF per Share

Wuhan Easy Diagnosis Biomedicine Co (SZSE:002932) Cyclically Adjusted FCF per Share : ¥2.44 (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Wuhan Easy Diagnosis Biomedicine Co Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Wuhan Easy Diagnosis Biomedicine Co's adjusted free cash flow per share data for the fiscal year that ended in Dec. 2023 was ¥1.244. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is ¥2.44 for the trailing ten years ended in Dec. 2023.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 98.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Wuhan Easy Diagnosis Biomedicine Co was 98.90% per year. The lowest was 98.90% per year. And the median was 98.90% per year.

As of today (2024-06-21), Wuhan Easy Diagnosis Biomedicine Co's current stock price is ¥ 17.88. Wuhan Easy Diagnosis Biomedicine Co's Cyclically Adjusted FCF per Share for the fiscal year that ended in Dec. 2023 was ¥2.44. Wuhan Easy Diagnosis Biomedicine Co's Cyclically Adjusted Price-to-FCF of today is 7.33.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Wuhan Easy Diagnosis Biomedicine Co was 96.46. The lowest was 6.75. And the median was 44.07.


Wuhan Easy Diagnosis Biomedicine Co Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Wuhan Easy Diagnosis Biomedicine Co's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Wuhan Easy Diagnosis Biomedicine Co Cyclically Adjusted FCF per Share Chart

Wuhan Easy Diagnosis Biomedicine Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.31 0.76 2.37 2.44

Wuhan Easy Diagnosis Biomedicine Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 2.44 -

Competitive Comparison of Wuhan Easy Diagnosis Biomedicine Co's Cyclically Adjusted FCF per Share

For the Medical Devices subindustry, Wuhan Easy Diagnosis Biomedicine Co's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Wuhan Easy Diagnosis Biomedicine Co's Cyclically Adjusted Price-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Wuhan Easy Diagnosis Biomedicine Co's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Wuhan Easy Diagnosis Biomedicine Co's Cyclically Adjusted Price-to-FCF falls into.



Wuhan Easy Diagnosis Biomedicine Co Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Wuhan Easy Diagnosis Biomedicine Co's adjusted Free Cash Flow per Share data for the fiscal year that ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=1.244/114.7809*114.7809
=1.244

Current CPI (Dec. 2023) = 114.7809.

Wuhan Easy Diagnosis Biomedicine Co Annual Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201412 0.086 99.000 0.100
201512 0.289 100.600 0.330
201612 0.120 102.600 0.134
201712 0.006 104.500 0.007
201812 0.035 106.500 0.038
201912 -0.045 111.200 -0.046
202012 1.588 111.500 1.635
202112 4.841 113.108 4.913
202212 16.095 115.116 16.048
202312 1.244 114.781 1.244

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Wuhan Easy Diagnosis Biomedicine Co  (SZSE:002932) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Wuhan Easy Diagnosis Biomedicine Co's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=17.88/2.44
=7.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Wuhan Easy Diagnosis Biomedicine Co was 96.46. The lowest was 6.75. And the median was 44.07.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Wuhan Easy Diagnosis Biomedicine Co Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Wuhan Easy Diagnosis Biomedicine Co's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Wuhan Easy Diagnosis Biomedicine Co (SZSE:002932) Business Description

Traded in Other Exchanges
N/A
Address
No. 1 Dongxin Road, 2 Floor, Building E, International Students Pioneer Park, Guandong Science and Technology Park, Donghu Development Zone, Hubei, Wuhan, CHN, 430075
Wuhan Easy Diagnosis Biomedicine Co Ltd is engaged in the research and development, production and sales of in vitro diagnostic reagents and supporting instruments and mobile ECG products. The company's product profile consists of Molecular diagnosis, Chemiluminescence, Blood gas analysis, and others. It also provides various other solutions such as Mingde Biomolecular Diagnostic Service Solution, Mingde Biothoracic Center Solution, POCT Solution, Remote ECG network construction solution, and others.
Executives
Wang Rui Directors, executives
Wang Jian Fei Director

Wuhan Easy Diagnosis Biomedicine Co (SZSE:002932) Headlines

No Headlines